“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

Breast cancer is the most common malignancy among women globally, with an increasing incidence rate that poses a significant threat to women's health worldwide. Molecular typing aids in the precise classification and stratified treatment of breast cancer. The continuous development of immunotherapy and targeted therapy offers new treatment options for patients with different types. At the recent 2023 China Conference of Integrated Oncology (CCHIO 2023), "Tumor Watch" had the opportunity to interview Professor Zhang Jin from Tianjin Medical University Cancer Hospital at the venue. Professor Zhang discussed the current state of breast cancer research in China, reviewed the evolution of breast cancer treatment strategies, and shared insights into the precision treatment of patients with different types.
ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

At this year's recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Zhang Guiming from Qingdao University Affiliated Hospital, a well-known young expert in the field of prostate cancer, for an in-depth interview to explain the three new developments related to talazoparib's precision treatment recently announced at ESMO. Here, we provide a summary of the interview for the readers.
ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 inaugurated its opening session, heralding a landmark event in the world of oncology. Hosted in the prestigious Hall 406, this congress brings together the brightest minds in cancer research and treatment, uniting a global community in the fight against this challenging disease. The opening ceremony featured the traditional Dragon Dance, symbolizing prosperity and health. This cultural performance underscored the congress's commitment to diversity and inclusivity, setting a vibrant tone for the event. After the opening address, ESMO also commended society in Asia for their outstanding contributions in promoting international cooperation and exchanges. Dr. Donglu Zhao accepted the certificate of appreciation on behalf of the Chinese Society of Clinical Oncology (CSCO).
ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".
ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. "Oncology Frontier" has specially invited Professor Yao Zhu from Fudan University's affiliated Cancer Hospital to provide an in-depth interpretation of these research developments.
ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".
WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

The 2023 World Conference on Lung Cancer (WCLC), held from September 9th to 12th at the Singapore, provided a platform for oncology experts to delve into cutting-edge developments. The “Oncology Frontier” team reports on-the-spot international cutting-edge developments and witnesses the progress of China's anti-cancer cause on the international stage. Renowned oncologist Dr. Baohui Han, from the Shanghai Chest Hospital, delivered a significant address at the conference. In an exclusive interview with “Oncology Frontier”, Dr. Han shared profound insights into the latest breakthroughs and contemplations on hot topics in targeted therapy for lung cancer.
2023 WCLC | Dr. Caicun Zhou Discusses Latest Results on EGFR exon20ins Mutation

2023 WCLC | Dr. Caicun Zhou Discusses Latest Results on EGFR exon20ins Mutation

The World Conference on Lung Cancer (WCLC), a significant academic exchange event in the global lung cancer field, was successfully held in Singapore from September 9 to 12, 2023. The conference revealed many important research findings, bringing about a new era of treatment in clinical practice. Among them, the EGFR Exon20 insertion mutation (EGFR exon20ins) as the third major EGFR mutation has garnered widespread attention. In recent years, novel treatments for this mutation have continuously emerged. At the WCLC, the phase 1b results of the FAVOUR study on the treatment of EGFR exon20ins-positive advanced non-small cell lung cancer (NSCLC) with furmonertinib were reported. " Oncology Frontier " had the privilege of interviewing Dr. Caicun Zhou, a leading figure in the field of lung cancer treatment at Shanghai Pulmonary Hospital and Tongji University School of Medicine. Dr. Zhou shared the latest treatments of EGFR exon20ins-positive NSCLC.
WCLC Interview | Dr. Clarissa Baldotto: Treatment strategies after failure of immunotherapy for lung cancer

WCLC Interview | Dr. Clarissa Baldotto: Treatment strategies after failure of immunotherapy for lung cancer

The 2023 World Conference of Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was grandly held in Singapore from September 9th to 12th. At the WCLC conference, Dr. Clarissa Baldotto, President of the Brazilian Group of Thoracic Oncology, was invited by “Oncology frontier” to talk about the treatment strategies for lung cancer after immunotherapy failure, as well as the current status and future development of oncology in Brazil.